Filter Results
Clinical Studies
Results filtered:Study status:
Open
Contact Us for the Latest Status
Closed for Enrollment
Open
-
A Phase 1, Open-label Study To Evaluate Safety, Tolerability, And Pharmacokinetics Of An Anti-LILRB2 / PD-L1 Bispecific Antibody SPX- 303 In Patients With Solid Tumors
Rochester, Minn.,
Scottsdale/Phoenix, Ariz.,
Jacksonville, Fla.
Part 1 of this study is an open-label, dose-escalation, and safety expansion study of an anti-LILRB2 / anti-PD-L1 bispecific antibody SPX- 303 in patients with solid tumors. Part 2 of this study is an indication-specific dose expansion study of SPX-303.
-
A Phase 1/2 Multicenter, Open-label, Dose-escalation, Safety, Pharmacodynamic, And Pharmacokinetic Study Of Q901 Administered Via Intravenous Infusion In Adult Patients With Selected Advanced Solid Tumors With A Cohort Expansion At The Recommended Phase 2 Dose
Rochester, Minn.,
Scottsdale/Phoenix, Ariz.,
Jacksonville, Fla.
The purpose of part one of this study is to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and safety profile of Q901 monotherapy when administered via intravenous (IV) infusion once-weekly (QW) for 4 weeks and once every 2 weeks (Q2W) thereafter. Also, to establish for future clinical development the recommended Phase 2 dose (RP2D) of Q901 monotherapy when administered via IV infusion QW for 4 weeks and Q2W thereafter.
The purpose of part two of this study is to evaluate safety and tolerability and evidence of anticancer activity of Q901 as monotherapy and in combination with pembrolizumab. In Part 2 Cohort 1, an expansion phase at the established RP2D will be undertaken in participants with selected advanced solid tumors. In Part 2 Cohort 2, a safety run in and expansion phase will be undertaken with Q901 at the RP2D administered in combination with pembrolizumab (400 mg Q6W) in participants with advanced solid tumors.
-
Obesity And Inflammation Impact Immunotherapy Outcomes In Renal Cancer
Scottsdale/Phoenix, Ariz.
The purpose of this study is to determine the extent to which immunotherapy failure in kidney cancer patients with obesity is associated with prolonged, body-wide inflammation. Hypothesis: In patients with obesity, high sustained inflammation will be associated with poor immunotherapy outcomes, high inflammation that resolves during therapy will be associated with better outcomes, and sustained low inflammation will be associated with the best therapy outcomes. These general trends will also hold true for non-obese RCC patients, although the magnitude of the response rates may be shifted.
-
Phase 1, First-in-Human, Multicenter, Open-Label Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Preliminary Antitumor Activity Of KO-2806 When Administered As Monotherapy And In Combination Therapy In Adult Patients With Advanced Solid Tumors
Jacksonville, Fla.,
Rochester, Minn.,
Scottsdale/Phoenix, Ariz.
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyl transferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.
Contact Us for the Latest Status
-
A Phase 2, Open-label, Multicenter Study Of IBI363 (PD1-IL2m) In Subjects With Advanced Solid Malignancies
Scottsdale/Phoenix, Ariz.,
Jacksonville, Fla.,
Rochester, Minn.
This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies.
.